Mozobil — Class III drug recall D-0704-2017
Terminated recall by Sanofi-Aventis U.S. LLC, reported 2017-05-17. Labeling: Incorrect or Missing Package Insert
| Recall number | D-0704-2017 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sanofi-Aventis U.S. LLC, Bridgewater, NJ, United States |
| Recall initiated | 2016-09-01 |
| Classified | 2017-05-11 |
| Reported by FDA | 2017-05-17 |
| Terminated | 2018-02-15 |
| Quantity | 2,133 vials |
| Reason classes | labeling |
| NDC | 00024-5862, 00024-5862-01 |
| Lot numbers | 04/18, 5RZ001C, 5RZ001D |
Product
Mozobil (plerixafor injection) 24mg/1.2mL (20mg/mL), For Single Use Only, Rx Only, Manufactured by: Genzyme Corporation 500 Kendall Street, Cambridge, MA 02412 USA NDC: 0024-5862-01
Reason for recall
Labeling: Incorrect or Missing Package Insert
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0704-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.